Taxotere-Enoxaparin-(ENOXA)-Study
Taxotere-Enoxaparin-(ENOXA)-Study: 1st-Line Docetaxel-Platin Chemotherapy as single therapy or in combination with Enoxaparin in patients aged older than 18 years with locally advanced or metastatic non-small cell lung cancer (stadium IIIb/IV), a phase III study. Study hypothesis: Increase of progressive free survival from 5 to 7.5 months.
Non-small Cell Lung Cancer
DRUG: Enoxaparin|OTHER: No Enoxaparin
Progressive free survival, monthly
Overall survival, monthly|RECIST, monthly|Quality of life, every three months|thromboembolic complications, monthly|safety of long term application of Enoxaparin, monthly|overall toxicity, monthly
Taxotere-Enoxaparin-(ENOXA)-Study: 1st-Line Docetaxel-Platin Chemotherapy as single therapy or in combination with Enoxaparin in patients aged older than 18 years with locally advanced or metastatic non-small cell lung cancer (stadium IIIb/IV), a phase III study. Study hypothesis: Increase of progressive free survival from 5 to 7.5 months.